CuraScript SD

curascriptsd.com

Anchored by Express Scripts, CuraScript SD complements the Accredo specialty pharmacy services by offering healthcare providers seamless access to essential therapies and customized business solutions to enhance practice.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

MIKART AND NANO PHARMASOLUTIONS HAVE ENTERED INTO A COLLABORATION AGREEMENT TO MANUFACTURE CLINICAL TRIAL MATERIALS USING NANOTRANSFORMER™ TECHNOLOGY

Mikart, LLC Nano and PharmaSolutions, Inc. | October 12, 2022

news image

Mikart, LLC a comprehensive contract development and manufacturing organization announced that it has entered into a collaboration agreement with Nano PharmaSolutions, Inc. an innovative nanotechnology company that has a proprietary NanoTransformer™ that enhances the solubility of pharmaceutical active ingredients. "We are excited to bring this new technology from preclinical stage to a GMP clinical phase manufacturing environment. This differentia...

Read More

Views and Analysis

CMIC AND LOKAVANT COLLABORATE TO DEPLOY MACHINE LEARNING-POWERED CLINICAL TRIAL INTELLIGENCE PLATFORM

CMIC | June 25, 2021

news image

CMIC Co., Ltd., a leading Japanese Contract Research Organization (CRO), and Lokavant, a leading clinical trial intelligence company, announced today that they have agreed to use Lokavant's predictive analytics capabilities to assist CMIC's clinical operations. This strategic collaboration, Lokavant Oversight, monitoring, and operational risk management platform, will be implemented throughout CMIC studies. CMIC was the first firm in Japan to provide CRO services, and the ...

Read More

Business Insights

ACORDA THERAPEUTICS AND BIOPAS LABORATORIES ANNOUNCE AGREEMENT TO COMMERCIALIZE INBRIJA® IN LATIN AMERICA

Acorda Therapeutics, Inc. | May 12, 2022

news image

Acorda Therapeutics, Inc. and Biopas Laboratorie announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of ...

Read More

Business Insights, PHARMA TECH

XTALPI PARTNERS WITH SINGAPORE'S DRUG DISCOVERY PLATFORM TO FIND BETTER CANCER TREATMENTS

XtalPi Inc. | December 29, 2022

news image

One of the pioneering pharmaceutical technology companies - XtalPi, powered by artificial intelligence (AI) and automation, has recently announced a strategic collaboration with Singapore's national platform for drug discovery and development, the Experimental Drug Development Centre (EDDC), which is hosted by the Agency for Science, Technology, and Research of Singapore (A*STAR). The goal of this partnership is to find novel treatment candidates for non-small cell lung cancer (NSCLC)....

Read More
news image

Business Insights

MIKART AND NANO PHARMASOLUTIONS HAVE ENTERED INTO A COLLABORATION AGREEMENT TO MANUFACTURE CLINICAL TRIAL MATERIALS USING NANOTRANSFORMER™ TECHNOLOGY

Mikart, LLC Nano and PharmaSolutions, Inc. | October 12, 2022

Mikart, LLC a comprehensive contract development and manufacturing organization announced that it has entered into a collaboration agreement with Nano PharmaSolutions, Inc. an innovative nanotechnology company that has a proprietary NanoTransformer™ that enhances the solubility of pharmaceutical active ingredients. "We are excited to bring this new technology from preclinical stage to a GMP clinical phase manufacturing environment. This differentia...

Read More
news image

Views and Analysis

CMIC AND LOKAVANT COLLABORATE TO DEPLOY MACHINE LEARNING-POWERED CLINICAL TRIAL INTELLIGENCE PLATFORM

CMIC | June 25, 2021

CMIC Co., Ltd., a leading Japanese Contract Research Organization (CRO), and Lokavant, a leading clinical trial intelligence company, announced today that they have agreed to use Lokavant's predictive analytics capabilities to assist CMIC's clinical operations. This strategic collaboration, Lokavant Oversight, monitoring, and operational risk management platform, will be implemented throughout CMIC studies. CMIC was the first firm in Japan to provide CRO services, and the ...

Read More
news image

Business Insights

ACORDA THERAPEUTICS AND BIOPAS LABORATORIES ANNOUNCE AGREEMENT TO COMMERCIALIZE INBRIJA® IN LATIN AMERICA

Acorda Therapeutics, Inc. | May 12, 2022

Acorda Therapeutics, Inc. and Biopas Laboratorie announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of ...

Read More
news image

Business Insights, PHARMA TECH

XTALPI PARTNERS WITH SINGAPORE'S DRUG DISCOVERY PLATFORM TO FIND BETTER CANCER TREATMENTS

XtalPi Inc. | December 29, 2022

One of the pioneering pharmaceutical technology companies - XtalPi, powered by artificial intelligence (AI) and automation, has recently announced a strategic collaboration with Singapore's national platform for drug discovery and development, the Experimental Drug Development Centre (EDDC), which is hosted by the Agency for Science, Technology, and Research of Singapore (A*STAR). The goal of this partnership is to find novel treatment candidates for non-small cell lung cancer (NSCLC)....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us